Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Arch Biopartners - Real shareholder growth

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Nov 17, 2021 9:54pm

171 Views

Post# 34139001

Arch Biopartners - Real shareholder growth

$AGN 100-1 consolidation to try faking their way to Nasdaq , $Xrtx 11-1 consolidation to try faking their way to the Nasdaq. $Arch is in the NYSE range and not to far from taking shareholders possibly to a higher exchange based on shareholder wealth. If their is a signal in the third party reviewed human data, whatever exchange management chooses, will be from a position of strength.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading